Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

85.87 +0.83 (+0.98%)
Delayed Quote Updated: 2:19 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? ↗
Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech has a large cash cushion and a growing cancer pipeline, but its COVID vaccine... 
Via The Motley Fool
News headline image
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027 ↗
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027? ↗
Axsome Therapeutics is growing quickly but is not yet profitable. BioNTech has a big cash cushion but is losing its COVID vaccine sales. 
Via The Motley Fool
News headline image
BioNTech (BNTX) Q3 2026 Earnings Call Transcript ↗
Oncology pivot and a CEO transition shape a quarter with a revised revenue outlook. 
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Q3 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the... 
Via MarketBeat
Topics Earnings
News headline image
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
From Biotech Insider
Via GlobeNewswire
News headline image
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗
It has been a volatile year for the biotech. 
Via The Motley Fool
News headline image
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials. 
Via The Motley Fool
News headline image
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick? ↗
Is bigger always better? Not necessarily. 
Via The Motley Fool
News headline image
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? ↗
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Investors buying this biotech stock now will get its pipeline essentially for free. 
Via The Motley Fool
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
From BioNTech SE
Via GlobeNewswire
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Both have attracted considerable attention from Wall Street recently. 
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.